Grifols SA is expected to post Q2 2026 revenue of $2.01 billion and EPS of $0.27, with its current share price of $8.45 sitting significantly under the $12.10 analyst consensus target.
Investors are laser-focused on the company's free cash flow generation and its ability to reduce leverage following a period of intense balance sheet scrutiny.
The market is looking for confirmation that the Net Debt-to-EBITDA ratio is descending toward the 3.5x management target after the divestment of Shanghai RAAS.
Success in reducing plasma collection costs and improving operational margins in the Biotest segment remains vital for restoring investor confidence in the long-term growth trajectory.